These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 3880372)

  • 41. Studies on the effects of betabeta'-iminodipropionitrile and O-(beta-hydroxyethyl)-rutoside on ADP-activated aggregation of rat platelets in relation to the development of diabetic microangiopathy.
    Pollock J; Heath H
    Biochem Pharmacol; 1975 Feb; 24(3):397-400. PubMed ID: 1125047
    [No Abstract]   [Full Text] [Related]  

  • 42. A double-blind trial of O-(beta-hydroxyethyl)-rutoside in patients with chronic venous insufficiency.
    Bergqvist D; Hallböök T; Lindblad B; Lindhagen A
    Vasa; 1981; 10(3):253-60. PubMed ID: 7025500
    [No Abstract]   [Full Text] [Related]  

  • 43. Alterations in the hematological profile in rat following whole body gamma radiation with and without venoruton pretreatment.
    Kanwar KC; Verma A
    J Environ Pathol Toxicol Oncol; 1992; 11(4):235-9. PubMed ID: 1507075
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of O-(beta-hydroxyethyl)-rutosides on function and structure of the ganglion cells.
    Blasius W; Leusser K; Merker G
    Arzneimittelforschung; 1976; 26(9):1645-50. PubMed ID: 1036693
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Behavior and significance of beta-thromboglobulin in chronic obliterating arteriopathy of the lower limbs. Preliminary research].
    Binaghi F; Valle E; Manconi E; Pitzus F
    Cardiologia; 1982 Nov; 27(11):1043-9. PubMed ID: 6085827
    [No Abstract]   [Full Text] [Related]  

  • 46. [HPLC determination of troxerutin in plasma and urine following oral administration in man].
    Dittrich P; Ostrowski J; Beubler E; Schraven E; Kukovetz W
    Arzneimittelforschung; 1985; 35(4):765-7. PubMed ID: 4015744
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The effect of O-betahydroxyethyl-rutosides (HR) on the number of platelet-leukocyte aggregates in patients with occlusive arterial disease.
    Bielawiec M; Kiersnowska-Rogowska B; Dabrowski S; Lukjan H
    Folia Haematol Int Mag Klin Morphol Blutforsch; 1979; 106(1):103-8. PubMed ID: 88383
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The flavonoid 7-mono-O-(β-hydroxyethyl)-rutoside is able to protect endothelial cells by a direct antioxidant effect.
    Lemmens KJ; van de Wier B; Vaes N; Ghosh M; van Zandvoort MA; van der Vijgh WJ; Bast A; Haenen GR
    Toxicol In Vitro; 2014 Jun; 28(4):538-43. PubMed ID: 24412621
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Dose-response study with O-(beta-hydroxyethyl)-rutoside oral solution].
    Nocker W; Diebschlag W
    Vasa; 1987; 16(4):365-9. PubMed ID: 3321740
    [No Abstract]   [Full Text] [Related]  

  • 50. The disposition and metabolism of 3',4',7-tri-O-(beta-hydroxyethyl)rutoside and 7-mono-O-(beta-hydroxyethyl)rutoside in the mouse.
    Hackett AM; Griffiths LA
    Xenobiotica; 1977 Oct; 7(10):641-51. PubMed ID: 910465
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Stimulation and inhibition of biosynthesis of prostaglandins in human skin by some hydroxyethylated rutosides.
    Arturson G; Jonsson CE
    Prostaglandins; 1975 Dec; 10(6):941-8. PubMed ID: 1208886
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Benzopyrone in the therapy of postreconstructive edema. A clinical double-blind study].
    Becker HM; Niedermaier G; Orend KH
    Fortschr Med; 1985 Jun; 103(21):593-6. PubMed ID: 4018687
    [No Abstract]   [Full Text] [Related]  

  • 53. Efficacy of O-(beta-hydroxyethyl)-rutosides at high dosage in counteracting the unwanted activity of oral contraceptives on venous function.
    Cappelli R; Pecchi S; Oberhauser V; Forconi S; Di Perri T
    Int J Clin Pharmacol Res; 1987; 7(4):291-9. PubMed ID: 3596872
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Erythrocyte deformability in patients with arteriosclerosis obliterans of lower limbs.
    Lukjan H; Rość D; Chyzy R; Szpak A
    Acta Med Pol; 1983; 24(1-4):55-63. PubMed ID: 6679687
    [No Abstract]   [Full Text] [Related]  

  • 55. [Lipoproteins in arteriosclerosis obliterans of the lower limbs].
    Sznajderman M; Rymaszewski Z; Kancelarczyk WL; Kuczyńska K
    Pol Arch Med Wewn; 1983 Sep; 70(3):125-30. PubMed ID: 6657491
    [No Abstract]   [Full Text] [Related]  

  • 56. Pharmacokinetics of mono-3'- and mono-4'-0-(beta-hydroxyethyl)-rutoside derivatives, after single doses of Venoruton powder in healthy volunteers.
    Kienzler JL; Sallin D; Schifflers MH; Ghika A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):395-402. PubMed ID: 12242598
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of Troxerutin on the hemorheological parameters of patients with moderate arterial hypertension.
    Gueguen-Duchesne M; Durand F; Le Goff MC; Genetet B
    Prog Clin Biol Res; 1988; 280():401-6. PubMed ID: 3174703
    [No Abstract]   [Full Text] [Related]  

  • 58. Evaluation of capillary permeability and microcirculation in patients with chronic venous hypertension treated with venoruton by the vacuum suction chamber (VSC) device and laser-Doppler flowmetry.
    Belcaro G; D'Aulerio A; Rulo A; Candiani C
    Phlebologie; 1988; 41(4):847-56. PubMed ID: 3073400
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Comparison between the efficacy and tolerability of oxerutins and troxerutin in the treatment of patients with chronic venous insufficiency.
    Rehn D; Golden G; Nocker W; Diebschlag W; Lehmacher W
    Arzneimittelforschung; 1993 Oct; 43(10):1060-3. PubMed ID: 8267669
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Blood coagulation in arteriosclerosis obliterans of the lower limbs].
    Chubar' SV
    Vrach Delo; 1978 Oct; (10):21-5. PubMed ID: 716352
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.